In light of this week's reports that banks were hacked, a cybersecurity expert rates the best and worst industries at protecting your online data.» Read More
Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.
Reckitt Benckiser plans to spin off its heroin-addiction treatment in the next 12 months as sales slide under pressure from rival versions.
Hospira could use an acquisition of the Danone business to redomicle its tax headquarters in France in a deal known as a tax inversion.
Additional rules and enforcement from federal agencies have a majority of employers worried about how to run their firms.
Big variations in price from provider to provider could be adding to your bills—even if you're insured.
Surely Congress didn't mean to include a "poison pill" for the Affordable Care Act when it passed it, says law professor Tim Jost.
States might need to spend only hundreds of dollars or less to protect Obamacare subsidies for residents currently enrolled in HealthCare.gov plans.
GlaxoSmithKline faces new corruption allegations in Syria, where it has been accused of paying bribes to secure business.
CRE, one of the worst of the superbugs, is spreading in some hospitals, and there's worry that cases are under-reported.
A Liberian man is being tested for the deadly Ebola virus in Nigeria's commercial capital of Lagos, a megacity of 21 million people.
Health care workers with less than a four-year degree make up 61% of the industry's 12.1 million employees, USA Today reports.
The federal government says 10.3 million adults have become newly insured since the launch of Obamacare last fall.
Roche confirmed its full-year outlook, but posted profit that missed expectations following an impairment charge at its diagnostics business.
Gilead Sciences delivered quarterly earnings and revenue that topped analysts' expectations on Wednesday.
When Senate Majority Leader Harry Reid went "nuclear" last winter, he just might have saved a major part of Obamacare from a huge challenge it faces.
The GAO said that 11 out of 12 fictitious applicants secured government subsidized healthcare. NBC News reports.
U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.
After a split ruling on Obamacare from the courts, who gets the last word? Law professor Dan Eaton weighs in.
Puma Biotechnology's experimental breast cancer drug met its main goal in a late-stage trial, but the options market is sensing something funky.
In a dramatic split decision, two federal appellate panels disagreed on the legality of billions of dollars in government subsidies for Obamacare.
Get the best of CNBC in your inbox